In summary, although daratumumab induces on-tumor activity, through several CD38 immune-mediated and CD38-modulating actions, and induces immunomodulatory effects in patients with MM, its effects on CD38-expressing R/R NKTCL tumor cells as observed in the NKT2001 study were suboptimal. Here, CD38 is linked to Miyoshi myopathy.